This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentEventsMaterialsVideosLet's connectLet's ConnectPfizer medical information

Menu

Close

AboutAboutHeritageMechanism Of ActionPatient ProfilesStable SHL PatientsPatient on the MovePatients Currently Taking an EHLPatient Actively Involved in SportAboutPurification ProcessDosingRecommended Dosing SchedulesProphylaxisOn-demandAdministrationDose AdministrationEfficacy and SafetyEfficacy and SafetyClinical EfficacySafety ProfileMonitoringPatient Reported OutcomesReal-world dataSupport & ServicesSupport & ServicesPrescribing InformationExplore MaterialsExplore VideosLatest ArticlesExplore Events
DosingRecommended dose modificationsDose Administration

Dose Administration

BeneFIX® is administered by intravenous infusion after reconstitution of the lyophilised powder for solution for injection with sterile 0.234% w/v sodium chloride solution.1

BeneFIX® can be administered as an on-demand or a prophylactic treatment.1

  

Dosing That Enables Individualised Coverage for Your Patients1,2

  

Needleless reconstitution 

  

  • Pre-filled diluent syringe1
  • Needleless reconstitution3
  • Clear plastic vial adapter1

  

Dosing flexibility

  • Broad range of vial sizes to individualise FIX coverage for patients1
     
  • 5-mL reconstitution volume for all vial sizes1
     
  • Rate of administration should be determined by the patient’s level of comfort. In most of the cases, an infusion rate of up to 4 mL per minute has been used1

Storage

  

Store between 2 - 30 °C for the entire shelf life (2 years)1:

  • Do not freeze1
     

  • The reconstituted product does not contain a preservative and should be used immediately, but no longer than 3 hours after reconstitution1
     

  • Chemical and physical in-use stability has been demonstrated for 3 hours at temperatures up to 25 °C1

  • For complete information on the safety profile and proper usage, consult the local product document1

Instructional Infusion Video

  

BeneFIX® branded instructional video designed to show patients how to infuse with BeneFIX®.

  

Coming Soon...

  

  

References:

Local product document, Nonacog alfa (recombinant coagulation factor IX), BeneFIX® : LPDBEN062022.Shapiro AD, Korth-Bradley J, Poon MC. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. Haemophilia. 2005;11(6):571-582.Wyeth receives FDA approval for new BeneFIX features that provide hemophilia B patients a simpler and more convenient preparation process for recombinant factor IX. BioSpace. Accessed May 2, 2022. https://www.biospace.com/article/releases/wyeth-receives-fda-approval-for-new-benefix-features-that-provide-hemophilia-b-patients-a-simpler-and-more-convenient-preparation-process-for-recombin/

  

PP-BEN-IND-0038 June 2023

Dosing flexibility

Example

Administration

About

BeneFIX® is a recombinant coagulation FIX. Find out how BeneFIX® works

Learn more


Efficacy and Safety

Proven efficacy and protection across dosing regimen

Review efficacy profile


Real-world Data

See how BeneFIX® performs in real-life settings.

Review real-world data
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-BEN-IND-0038

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

Copyright © 2023 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
For the use only of Registered medical practitioners* or a Hospital or a Laboratory

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.

 

If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered medical practitioner*, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-DOL-IND-0251 18 JAN 2023Yes No
You are now leaving PfizerPro website
​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?
PP-DOL-IND-0251 18 JAN 2023